Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVd vs Vd in NDMM Patients With Renal Injury
NCT05432414Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Renji Hospital. Primary endpoint: Very Good Partial Response at 12 weeks. Status: unknown.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05432414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432414.